Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on Fluid Removal Using Furosemide and Amiloride Hydrochloride in ICU Patients with Fluid Overload

Fast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a treatment for patients experiencing fluid overload, a condition where there is too much fluid in the body, often seen in critically ill patients in intensive care units (ICU). The treatment being tested is furosemide, a medication that helps remove excess fluid from the body. The study will compare the effects of furosemide with a placebo, which is a substance with no active medication, to see if furosemide can help patients recover more quickly and spend more days alive and out of the hospital within 90 days.

The purpose of the study is to determine whether using furosemide for fluid removal is more beneficial than allowing the body to remove fluid on its own. Participants in the study will receive either furosemide or a placebo through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor the number of days patients are alive and out of the hospital, as well as other important health outcomes, over a period of 90 days and up to one year.

Throughout the study, researchers will also look at other factors such as overall survival rates, the number of days patients can live without needing life support, and any serious side effects. Additionally, the study will assess the quality of life and cognitive function of participants after one year. This research aims to provide valuable insights into the management of fluid overload in ICU patients and improve treatment strategies for this condition.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the patient is confirmed to meet the inclusion criteria. This includes being 18 years or older, having an acute admission to the intensive care unit (ICU), and being clinically stable. Fluid accumulation must be at least 5% of the ideal body weight.

  2. Step 2

    Randomization

    The patient is randomly assigned to receive either the active medication, furosemide, or a placebo. The placebo is a sodium chloride 0.9% solution for intravenous infusion.

  3. Step 3

    Medication administration

    The assigned medication, either furosemide or placebo, is administered through an intravenous infusion. The dosage and frequency are determined by the study protocol, focusing on goal-directed fluid removal.

  4. Step 4

    Monitoring and assessment

    Throughout the trial, the patient's fluid balance, body weight, and clinical stability are closely monitored. The primary goal is to assess the number of days the patient is alive and out of the hospital by day 90.

  5. Step 5

    Follow-up evaluations

    At day 90, secondary outcomes such as all-cause mortality, days alive without life support, and any serious adverse events are evaluated. Further assessments include health-related quality of life and cognitive function at one year.

  6. Step 6

    Completion of the trial

    The trial is estimated to conclude by February 29, 2028. Final evaluations include long-term outcomes such as one-year mortality and quality of life assessments.

Who can join the trial?

11 criteria

  • The patient must be admitted to the Intensive Care Unit (ICU) for an urgent or emergency reason.
  • The patient must be 18 years old or older.
  • The patient must be considered clinically stable by the doctors. This means:
    • The patient's Mean Arterial Pressure (MAP) should be more than 50 mmHg. MAP is a measure of the average blood pressure in a person's arteries during one cardiac cycle.
    • The patient should not be receiving more than 20 micrograms per kilogram per minute of noradrenaline. Noradrenaline is a medication used to increase blood pressure.
    • The patient's lactate level should be less than 4.0 mmol/l. Lactate is a substance that can build up in the body when cells do not get enough oxygen.
    • The patient must have fluid accumulation that is estimated to be at least 5% of their ideal body weight. This is determined by:
      • Daily fluid balance, which is the difference between fluid intake and fluid output.
      • Cumulative fluid balance, which is the total fluid balance over a period of time.
      • Changes in body weight.
      • Clinical examination by a healthcare professional.
      • Both male and female patients can participate.
      • The study does not include vulnerable populations, which means groups that might need special protection or care.

Who cannot join the trial?

4 criteria

  • Patients who do not have **fluid overload**. This means they do not have too much fluid in their body.
  • Patients who are not in the **ICU**. The ICU is the Intensive Care Unit, a special part of the hospital for very sick patients.
  • Patients who are not adults. This means they are younger than 18 years old.
  • Patients who are part of a vulnerable population. This means they are in a group that needs special protection or care.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

RecruitingNot recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Furosemide is a medication used in this trial to help remove excess fluid from the body. It is often used in intensive care settings for patients who have too much fluid in their bodies, which can happen due to various medical conditions. The goal of using furosemide in this trial is to see if it can help patients recover more quickly by increasing the number of days they are alive and out of the hospital within 90 days.

What is already known about the treatment

Furosemide – Furosemide is typically administered orally or intravenously, depending on the patient's condition and the urgency of treatment. It is a well-established medication in medical literature, primarily used as a diuretic to treat fluid overload conditions, such as those seen in heart failure, liver cirrhosis, and kidney disease. The main therapeutic indication for furosemide is to promote the removal of excess fluid from the body, thereby reducing swelling and easing symptoms associated with fluid retention. At the molecular level, furosemide works by inhibiting the sodium-potassium-chloride co-transporter in the loop of Henle in the kidneys, leading to increased urine production and fluid excretion. It is classified pharmacologically as a loop diuretic.

Investigated diseases

Fluid Overload – Fluid overload is a condition where there is an excessive accumulation of fluid in the body, often due to an imbalance between fluid intake and excretion. This can lead to swelling, particularly in the legs and arms, and can affect the lungs, causing difficulty in breathing. It is commonly seen in patients with heart, kidney, or liver problems, where the body's ability to manage fluid balance is compromised. The condition can progress to cause discomfort, increased blood pressure, and stress on the heart and other organs. Managing fluid overload often involves monitoring fluid intake and output to prevent further complications.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-512186-14-00Protocol codeGODIF trialEstimated enrolment1 075 patientsSponsorRigshospitalet

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).